Blenrep (belantamab mafodotin-blmf) receives conditional approval in EU as a treatment for patients with relapsed for refractory multiple myeloma

This first-line inhibitor of BCMA has been approved for treatment of adults who have received ≥4prior therapies and whose disease is refractory to ≥1proteasome inhibitor, 1 immunomodulatory agent & an anti-CD38 monoclonal antibody, and whose disease has progressed on last therapy